arrow
T

Tracy Stockley

princess margaret cancer centre
H指数:35
被引数:5,528

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Contribution of Risk Factors, Including Polygenic Score, to the Multifactorial Risk Assessment for the Implementation of Personalized Breast Cancer Screening: Insights from the PERSPECTIVE: Integration and Implementation Project

包括多基因评分在内的风险因素对个性化乳腺癌筛查实施的多因素风险评估的贡献:来自PERSPECTIVE:整合与实施项目的见解

Cancers
IF4.4
2026-05-050
OA
Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18-gene panel

上皮性卵巢癌中应用下一代测序进行肿瘤和胚系检测:一项使用18基因面板的前瞻性配对比较研究

2025-10-050
OAAI
Indirect clinical validation for predictive biomarkers in oncology: International Quality Network for Pathology (IQN Path) Position Paper

肿瘤学中预测性生物标志物的间接临床验证:国际病理学质量网络(IQN Path)立场文件

2025-07-170
OA
Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations

TP53共突变在具有罕见可治疗驱动基因突变非小细胞肺癌患者中的预后和预测效果

2025-02-010
PRE
Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model (vol 34, pg 205, 2025)

将替代多基因风险评分纳入BOADICEA乳腺癌风险预测模型 (第34卷,205页,2025)

2025-01-090
OAAI
Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations
2024-12-230
OAAI
Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: a cost-consequence analysis using linked administrative data
2024-03-010
OAAI
Canadian Multicentric Pan-TRK (CANTRK) Immunohistochemistry Harmonization Study
2024-01-014
OAAI
Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma

循环肿瘤代谢物2-羟基戊二酸作为异柠檬酸脱氢酶 (IDH1/2) 突变型胆管癌的潜在生物标志物

2023-11-284
OAAI
Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia
2023-06-223
OAAI
A phase I study of binimetinib, a MEK inhibitor, in combination with pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC)
2023-04-142
PRE